{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T05:46:54Z","timestamp":1769233614857,"version":"3.49.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Human herpesviruses Epstein-Barr virus and cytomegalovirus are frequently detectable in the lungs of patients with idiopathic pulmonary fibrosis (IPF) and could contribute to disease pathogenesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>With the goal of inhibiting herpesvirus replication, we tested the safety and tolerability of adding valganciclovir to standard IPF therapy (pirfenidone).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a single-center, Phase I, double-blind, randomized, placebo-controlled trial comparing valganciclovir 900 mg daily with placebo in patients with IPF with serologic evidence of prior Epstein-Barr virus and\/or cytomegalovirus infection who were tolerating full-dose pirfenidone (2,403 mg\/d). Subjects were randomized to valganciclovir or placebo 2:1 for 12 weeks of active treatment with off-treatment follow-up for up to 12 months. The primary safety endpoint was the number of subjects discontinuing the study drug before completing 12 weeks of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-one subjects with IPF were randomized to valganciclovir (n = 20) or placebo (n = 11). All subjects completed assigned therapy except one subject in the valganciclovir group, who discontinued the study drug after developing a rash. The total number of adverse events was similar between study groups. In a prespecified analysis of secondary physiologic endpoints, we observed a trend toward improved forced vital capacity from randomization to Week 12 in valganciclovir-treated subjects (\u221210 ml; interquartile range [IQR], \u221265 to 70 ml) versus placebo-treated subjects (40 ml; IQR, \u2212130 to 60 ml), which persisted through 12 months of follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Valganciclovir is safe and well tolerated as an add-on therapy to pirfenidone in patients with IPF. Clinical trial registered with ClinicalTrials.gov (NCT02871401)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.202102-108oc","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T17:49:39Z","timestamp":1616176179000},"page":"1291-1297","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":9,"title":["A Phase I Randomized, Controlled, Clinical Trial of Valganciclovir in Idiopathic Pulmonary Fibrosis"],"prefix":"10.1093","volume":"18","author":[{"given":"Timothy S.","family":"Blackwell","sequence":"first","affiliation":[{"name":"Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine and"},{"name":"Department of Cell and Developmental Biology, Vanderbilt University, Nashville, Tennessee; and"},{"name":"Department of Veterans Affairs Medical Center, Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin C.","family":"Hewlett","sequence":"additional","affiliation":[{"name":"Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendi R.","family":"Mason","sequence":"additional","affiliation":[{"name":"Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Martin","sequence":"additional","affiliation":[{"name":"Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Del Greco","sequence":"additional","affiliation":[{"name":"Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guixiao","family":"Ding","sequence":"additional","affiliation":[{"name":"Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pingsheng","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine and"},{"name":"Department of Biostatistics, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa H.","family":"Lancaster","sequence":"additional","affiliation":[{"name":"Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E.","family":"Loyd","sequence":"additional","affiliation":[{"name":"Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosemarie B.","family":"Dudenhofer","sequence":"additional","affiliation":[{"name":"Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8217-6955","authenticated-orcid":false,"given":"Margaret L.","family":"Salisbury","sequence":"additional","affiliation":[{"name":"Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan A.","family":"Kropski","sequence":"additional","affiliation":[{"name":"Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine and"},{"name":"Department of Cell and Developmental Biology, Vanderbilt University, Nashville, Tennessee; and"},{"name":"Department of Veterans Affairs Medical Center, Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,8,1]]},"reference":[{"key":"2026012203491082600_bib1","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra1705751","article-title":"Idiopathic pulmonary fibrosis","volume":"378","author":"Lederer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012203491082600_bib2","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012203491082600_bib3","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012203491082600_bib4","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1586\/ers.10.73","article-title":"Viral infection and aging as cofactors for the development of pulmonary fibrosis","volume":"4","author":"Naik","year":"2010","journal-title":"Expert Rev Respir Med"},{"key":"2026012203491082600_bib5","doi-asserted-by":"crossref","first-page":"S186","DOI":"10.1513\/AnnalsATS.201502-088AW","article-title":"Viruses in idiopathic pulmonary fibrosis: etiology and exacerbation","volume":"12","author":"Moore","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203491082600_bib6","doi-asserted-by":"crossref","first-page":"L441","DOI":"10.1152\/ajplung.00335.2011","article-title":"Right place, right time: the evolving role of herpesvirus infection as a \u201csecond hit\u201d in idiopathic pulmonary fibrosis","volume":"302","author":"Kropski","year":"2012","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2026012203491082600_bib7","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1183\/09031936.97.10071433","article-title":"Viruses and idiopathic pulmonary fibrosis","volume":"10","author":"Egan","year":"1997","journal-title":"Eur Respir J"},{"key":"2026012203491082600_bib8","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0140-6736(84)90702-5","article-title":"Cryptogenic fibrosing alveolitis and Epstein-Barr virus: an association?","volume":"2","author":"Vergnon","year":"1984","journal-title":"Lancet"},{"key":"2026012203491082600_bib9","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1128\/JCM.41.6.2633-2640.2003","article-title":"Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis","volume":"41","author":"Tang","year":"2003","journal-title":"J Clin Microbiol"},{"key":"2026012203491082600_bib10","doi-asserted-by":"crossref","first-page":"L1119","DOI":"10.1152\/ajplung.00382.2007","article-title":"Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infection","volume":"294","author":"Lawson","year":"2008","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2026012203491082600_bib11","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1164\/ajrccm.159.4.9807077","article-title":"The detection of Epstein-Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis","volume":"159","author":"Stewart","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203491082600_bib12","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1183\/09031936.97.10092040","article-title":"Elevation of antibodies to cytomegalovirus and other herpes viruses in pulmonary fibrosis","volume":"10","author":"Yonemaru","year":"1997","journal-title":"Eur Respir J"},{"key":"2026012203491082600_bib13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1164\/rccm.201406-1162OC","article-title":"Extensive phenotyping of individuals at risk for familial interstitial pneumonia reveals clues to the pathogenesis of interstitial lung disease","volume":"191","author":"Kropski","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203491082600_bib14","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1128\/JVI.02487-09","article-title":"The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production","volume":"84","author":"Meng","year":"2010","journal-title":"J Virol"},{"key":"2026012203491082600_bib15","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203491082600_bib16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","author":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203491082600_bib17","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S2213-2600(18)30181-4","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial","volume":"6","author":"Maher","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2026012203491082600_bib18","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1001\/jama.2018.6129","article-title":"Effect of recombinant human pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis: a randomized clinical trial","volume":"319","author":"Raghu","year":"2018","journal-title":"JAMA"},{"key":"2026012203491082600_bib19","doi-asserted-by":"crossref","first-page":"240805","DOI":"10.1155\/2011\/240805","article-title":"Ganciclovir antiviral therapy in advanced idiopathic pulmonary fibrosis: an open pilot study","volume":"2011","author":"Egan","year":"2011","journal-title":"Pulm Med"},{"key":"2026012203491082600_bib20","doi-asserted-by":"crossref","first-page":"13051","DOI":"10.1073\/pnas.0804280105","article-title":"Short telomeres are a risk factor for idiopathic pulmonary fibrosis","volume":"105","author":"Alder","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026012203491082600_bib21","doi-asserted-by":"crossref","first-page":"e10680","DOI":"10.1371\/journal.pone.0010680","article-title":"Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations","volume":"5","author":"Diaz de Leon","year":"2010","journal-title":"PLoS One"},{"key":"2026012203491082600_bib22","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1164\/rccm.201809-1646OC","article-title":"Telomere length and use of immunosuppressive medications in idiopathic pulmonary fibrosis","volume":"200","author":"Newton","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203491082600_bib23","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/infdis\/jix263","article-title":"Valganciclovir for the suppression of Epstein-Barr virus replication","volume":"216","author":"Yager","year":"2017","journal-title":"J Infect Dis"},{"key":"2026012203491082600_bib24","doi-asserted-by":"crossref","first-page":"e1006507","DOI":"10.1371\/journal.ppat.1006507","article-title":"Tissue-specific control of latent CMV reactivation by regulatory T cells","volume":"13","author":"Almanan","year":"2017","journal-title":"PLoS Pathog"},{"key":"2026012203491082600_bib25","doi-asserted-by":"crossref","first-page":"L274","DOI":"10.1152\/ajplung.00028.2010","article-title":"Latent infection by \u03b3herpesvirus stimulates profibrotic mediator release from multiple cell types","volume":"300","author":"Stoolman","year":"2011","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2026012203491082600_bib26","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cell.2020.11.025","article-title":"Synergism of TNF-\u03b1 and IFN-\u03b3 triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes","volume":"184","author":"Karki","year":"2021","journal-title":"Cell"},{"key":"2026012203491082600_bib27","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1164\/rccm.200610-1426OC","article-title":"Control of virus reactivation arrests pulmonary herpesvirus-induced fibrosis in IFN-gamma receptor-deficient mice","volume":"175","author":"Mora","year":"2007","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/18\/8\/1291\/66337809\/annalsats_18_8_1291.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/18\/8\/1291\/66337809\/annalsats_18_8_1291.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:54:51Z","timestamp":1769072091000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/18\/8\/1291\/8419418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,1]]},"references-count":27,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8,1]]},"published-print":{"date-parts":[[2021,8,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202102-108oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8]]},"published":{"date-parts":[[2021,8,1]]},"assertion":[{"value":"2021-02-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}